%0 Journal Article
%T Myoinositol or D-chiro-inositol for PCOS symptoms in adolescents: a narrative review.
%A Sairally BZF
%A Dhillon-Smith RK
%A Jethwani G
%A Latthe P
%J J Pediatr Endocrinol Metab
%V 37
%N 2
%D 2024 Feb 26
%M 38117862
%F 1.52
%R 10.1515/jpem-2023-0458
%X <B>BACKGROUND: </B>Polycystic ovary syndrome (PCOS) treatment in adolescents currently focuses on lifestyle interventions, with pharmacological treatment options often limited to hormonal contraceptives. Several of these carry broad side-effect profiles and are not always accepted by young girls. There is growing interest in non-hormonal therapies for PCOS. We aimed to collate the evidence on the use of myoinositol or D-chiro-inositol in the improvement of PCOS symptoms in symptomatic adolescents.<BR><B>BACKGROUND: </B>A systematic literature review identifying key articles from inception to March 2023. Participants: Female adolescents (aged 12-19 years) with PCOS or PCOS-like features. Intervention: Myoinositol or D-chiro-inositol with or without additional interventions. Comparison: Any other treatment, including lifestyle interventions, hormonal therapy, metformin or no treatment. The main outcome measure were improvement in symptoms, quality of life and adverse effects.<BR><B>CONCLUSIONS: </B>Eight studies were included: two randomised open-label trials, one quasi-randomised and three non-randomised interventional studies, one case-control study and one cohort study. All studies showed improvements in some biochemical markers, metabolic parameters or clinical symptoms, but these were not reproducible across all studies.<BR><B>CONCLUSIONS: </B>The benefit of myoinositol in adolescents with PCOS remains unclear, with limited high-quality evidence. This review highlights the need for robustly conducted research to inform clinical practice.